197446-75-6

SB 220025 trihydrochloride may be used in p38-mediated cell signaling studies.

SB 220025 is a potentspecific inhibitor of human p38 mitogen-activated protein (MAP) kinasewith an IC50 value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED50 value of 7.5 mg/kg. at 30 mg/kgSB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further studythe effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis.